Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas.

Khawar Siddique, Niranjan Yanamandra, Meena Gujrati, Dzung Dinh, Jasti S. Rao, William Olivero

Research output: Contribution to journalArticle

Abstract

MMP-2, MMP-9, and uPA have been previously described as important to the invasive and metastatic potential of human tumors, including breast, lung, glioblastoma, and prostate. We examined the activity of these proteases and the levels of their inhibitors (TIMP-1 and TIMP-2) in a series of human meningioma tissue samples. Normal brain tissue did not show elevated levels of uPA, MMP-2 or MMP-9 activity. Meningiomas showed a mild, to moderate to significantly high level of uPA, MMP-2, and MMP-9. However, no increase in TIMP-1 or TIMP-2 levels was detected. Immunohistochemistry confirmed the assay findings and localized these molecules to the cell surface. The findings provide evidence for elevated levels of uPA and MMPs in meningiomas and suggest a therapeutic target for minimizing the malignant propensity of meningiomas using protease inhibitors.

Original languageEnglish (US)
Pages (from-to)289-294
Number of pages6
JournalInternational journal of oncology
Volume22
Issue number2
StatePublished - Jan 1 2003

Fingerprint

Matrix Metalloproteinase Inhibitors
Plasminogen Activators
Urokinase-Type Plasminogen Activator
Meningioma
Matrix Metalloproteinases
Tissue Inhibitor of Metalloproteinase-2
Tissue Inhibitor of Metalloproteinase-1
Glioblastoma
Protease Inhibitors
Prostate
Peptide Hydrolases
Immunohistochemistry
Breast Neoplasms
Lung
Brain

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Siddique, K., Yanamandra, N., Gujrati, M., Dinh, D., Rao, J. S., & Olivero, W. (2003). Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas. International journal of oncology, 22(2), 289-294.

Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas. / Siddique, Khawar; Yanamandra, Niranjan; Gujrati, Meena; Dinh, Dzung; Rao, Jasti S.; Olivero, William.

In: International journal of oncology, Vol. 22, No. 2, 01.01.2003, p. 289-294.

Research output: Contribution to journalArticle

Siddique, K, Yanamandra, N, Gujrati, M, Dinh, D, Rao, JS & Olivero, W 2003, 'Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas.', International journal of oncology, vol. 22, no. 2, pp. 289-294.
Siddique, Khawar ; Yanamandra, Niranjan ; Gujrati, Meena ; Dinh, Dzung ; Rao, Jasti S. ; Olivero, William. / Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas. In: International journal of oncology. 2003 ; Vol. 22, No. 2. pp. 289-294.
@article{208dc783ff474af29eb8bf94d6fc72a9,
title = "Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas.",
abstract = "MMP-2, MMP-9, and uPA have been previously described as important to the invasive and metastatic potential of human tumors, including breast, lung, glioblastoma, and prostate. We examined the activity of these proteases and the levels of their inhibitors (TIMP-1 and TIMP-2) in a series of human meningioma tissue samples. Normal brain tissue did not show elevated levels of uPA, MMP-2 or MMP-9 activity. Meningiomas showed a mild, to moderate to significantly high level of uPA, MMP-2, and MMP-9. However, no increase in TIMP-1 or TIMP-2 levels was detected. Immunohistochemistry confirmed the assay findings and localized these molecules to the cell surface. The findings provide evidence for elevated levels of uPA and MMPs in meningiomas and suggest a therapeutic target for minimizing the malignant propensity of meningiomas using protease inhibitors.",
author = "Khawar Siddique and Niranjan Yanamandra and Meena Gujrati and Dzung Dinh and Rao, {Jasti S.} and William Olivero",
year = "2003",
month = "1",
day = "1",
language = "English (US)",
volume = "22",
pages = "289--294",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas.

AU - Siddique, Khawar

AU - Yanamandra, Niranjan

AU - Gujrati, Meena

AU - Dinh, Dzung

AU - Rao, Jasti S.

AU - Olivero, William

PY - 2003/1/1

Y1 - 2003/1/1

N2 - MMP-2, MMP-9, and uPA have been previously described as important to the invasive and metastatic potential of human tumors, including breast, lung, glioblastoma, and prostate. We examined the activity of these proteases and the levels of their inhibitors (TIMP-1 and TIMP-2) in a series of human meningioma tissue samples. Normal brain tissue did not show elevated levels of uPA, MMP-2 or MMP-9 activity. Meningiomas showed a mild, to moderate to significantly high level of uPA, MMP-2, and MMP-9. However, no increase in TIMP-1 or TIMP-2 levels was detected. Immunohistochemistry confirmed the assay findings and localized these molecules to the cell surface. The findings provide evidence for elevated levels of uPA and MMPs in meningiomas and suggest a therapeutic target for minimizing the malignant propensity of meningiomas using protease inhibitors.

AB - MMP-2, MMP-9, and uPA have been previously described as important to the invasive and metastatic potential of human tumors, including breast, lung, glioblastoma, and prostate. We examined the activity of these proteases and the levels of their inhibitors (TIMP-1 and TIMP-2) in a series of human meningioma tissue samples. Normal brain tissue did not show elevated levels of uPA, MMP-2 or MMP-9 activity. Meningiomas showed a mild, to moderate to significantly high level of uPA, MMP-2, and MMP-9. However, no increase in TIMP-1 or TIMP-2 levels was detected. Immunohistochemistry confirmed the assay findings and localized these molecules to the cell surface. The findings provide evidence for elevated levels of uPA and MMPs in meningiomas and suggest a therapeutic target for minimizing the malignant propensity of meningiomas using protease inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=0042662973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042662973&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 289

EP - 294

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 2

ER -